Design of novel multi-epitope vaccines against severe acute respiratory syndrome validated through multistage molecular interaction and dynamics

Sukrit SrivastavaDepartment of Biotechnology, Mangalayatan University, Aligarh, India; ;Molecular Medicine Lab, School of Life Science, Jawaharlal Nehru University, New Delhi, India; Correspondence[email protected] [email protected]

http://orcid.org/0000-0003-0295-0272 View further author information

Mohit KamthaniaDepartment of Biotechnology, Mangalayatan University, Aligarh, India; ;Department of Biotechnology, Faculty of Life Sciences, Institute of Applied Medicines and Research, Ghaziabad, India; View further author information

Rajesh Kumar PandeyCenter of Experimental Medicine & Surgery, Institute of Medical Sciences, Banaras Hindu University, Varanasi, IndiaView further author information

Ajay Kumar SaxenaMolecular Medicine Lab, School of Life Science, Jawaharlal Nehru University, New Delhi, India; View further author information

Vaishali SaxenaMolecular Medicine Lab, School of Life Science, Jawaharlal Nehru University, New Delhi, India; View further author information

Santosh Kumar SinghCenter of Experimental Medicine & Surgery, Institute of Medical Sciences, Banaras Hindu University, Varanasi, IndiaView further author information

Rakesh Kumar SharmaDepartment of Biotechnology, Mangalayatan University, Aligarh, India; View further author information

Nishi SharmaDepartment of Biotechnology, Mangalayatan University, Aligarh, India; View further author information

show all

Pages 4345-4360 | Received 04 Aug 2018, Accepted 08 Nov 2018, Published online: 16 Jan 2019

Cite this article
https://doi.org/10.1080/07391102.2018.1548977
CrossMark

Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days

Full Article
Figures & data
References
Supplemental
Citations
Metrics
Reprints & Permissions
Read this article /doi/full/10.1080/07391102.2018.1548977?needAccess=true

Abstract

Severe acute respiratory syndrome (SARS) is endemic in South China and is continuing to spread worldwide since the 2003 outbreak, affecting human population of 37 countries till present. SARS is caused by the severe acute respiratory syndrome Coronavirus (SARS-CoV). In the present study, we have designed two multi-epitope vaccines (MEVs) composed of cytotoxic T lymphocyte (CTL), helper T lymphocyte (HTL) and B cell epitopes overlap, bearing the potential to elicit cellular as well as humoral immune response. We have used truncated (residues 10–153) Onchocerca volvulus activation-associated secreted protein-1 as molecular adjuvants at N-terminal of both the MEVs. Selected overlapping epitopes of both the MEVs were further validated for stable molecular interactions with their respective human leukocyte antigen class I and II allele binders. Moreover, CTL epitopes were further studied for their molecular interaction with transporter associated with antigen processing. Furthermore, after tertiary structure modelling, both the MEVs were validated for their stable molecular interaction with Toll-like receptors 2 and 4. Codon-optimized cDNA of both the MEVs was analysed for their potential high level of expression in the mammalian cell line (Human) needed for their further in vivo testing. Overall, the present study proposes in silico validated design of two MEVs against SARS composed of specific epitopes with the potential to cause a high level of SARS-CoV specific cellular as well as humoral immune response.

Communicated by Ramaswamy H. Sarma

Keywords:

Severe acute respiratory syndrome
severe acute respiratory syndrome coronavirus
epitope
multi-epitope vaccines
human transporter associated with antigen processing
Toll-like receptors
molecular docking
molecular dynamics simulation

Acknowledgements

We acknowledge the Advance Instrumentation Research Facility (AIRF) of the Jawaharlal Nehru University, New Delhi, for extending their advanced computational facility to conduct experiments.

Disclosure statement

The authors declare to have no competing interests.